Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Current Taxes Goodwill Goodwill & Intangibles Intangibles Inventory Land & Improvements Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Operating Leases Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Integra Lifesciences Holdings (IART) Finished Goods (2016 - 2017)

Integra Lifesciences Holdings' Finished Goods history spans 7 years, with the latest figure at $136.7 million for Q3 2017.

On a quarterly basis, Finished Goods changed N/A to $136.7 million in Q3 2017 year-over-year; TTM through Sep 2017 was $136.7 million, a N/A change, with the full-year FY2016 number at $128.0 million, changed N/A from a year prior.
Finished Goods hit $136.7 million in Q3 2017 for Integra Lifesciences Holdings, up from $128.0 million in the prior quarter.
Over the last five years, Finished Goods for IART hit a ceiling of $150.5 million in Q4 2014 and a floor of $128.0 million in Q4 2016.
Historically, Finished Goods has averaged $140.5 million across 4 years, with a median of $141.8 million in 2015.